Cargando…

Consumption of Low Dose Fucoxanthin Does Not Prevent Hepatic and Adipose Inflammation and Fibrosis in Mouse Models of Diet-Induced Obesity

Fucoxanthin (FCX) is a xanthophyll carotenoid present in brown seaweed. The goal of this study was to examine whether FCX supplementation could attenuate obesity-associated metabolic abnormalities, fibrosis, and inflammation in two diet-induced obesity (DIO) mouse models. C57BL/6J mice were fed eith...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Mi-Bo, Bae, Minkyung, Lee, Yoojin, Kang, Hyunju, Hu, Siqi, Pham, Tho X., Park, Young-Ki, Lee, Ji-Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9183127/
https://www.ncbi.nlm.nih.gov/pubmed/35684079
http://dx.doi.org/10.3390/nu14112280
_version_ 1784724213383299072
author Kim, Mi-Bo
Bae, Minkyung
Lee, Yoojin
Kang, Hyunju
Hu, Siqi
Pham, Tho X.
Park, Young-Ki
Lee, Ji-Young
author_facet Kim, Mi-Bo
Bae, Minkyung
Lee, Yoojin
Kang, Hyunju
Hu, Siqi
Pham, Tho X.
Park, Young-Ki
Lee, Ji-Young
author_sort Kim, Mi-Bo
collection PubMed
description Fucoxanthin (FCX) is a xanthophyll carotenoid present in brown seaweed. The goal of this study was to examine whether FCX supplementation could attenuate obesity-associated metabolic abnormalities, fibrosis, and inflammation in two diet-induced obesity (DIO) mouse models. C57BL/6J mice were fed either a high-fat/high-sucrose/high-cholesterol (HFC) diet or a high-fat/high-sucrose (HFS) diet. The former induces more severe liver injury than the latter model. In the first study, male C57BL/6J mice were fed an HFC diet, or an HFC diet containing 0.015% or 0.03% (w/w) FCX powder for 12 weeks to develop obesity-induced nonalcoholic steatohepatitis (NASH). In the second study, mice were fed an HFS diet or an HFS diet containing 0.01% FCX powder for 8 weeks. FCX did not change body weight gain and serum lipid profiles compared to the HFC or HFS controls. No significant differences were present in liver triglyceride and total cholesterol, hepatic fat accumulation, and serum alanine aminotransferase levels between control and FCX-fed mice regardless of whether they were on an HFC or HFS diet. FCX did not mitigate mRNA abundance of genes involved in lipid synthesis, cholesterol metabolism, inflammation, and fibrosis in the liver and white adipose tissue, while hepatic fatty acid β-oxidation genes were significantly elevated by FCX in both HFC and HFS feeding studies. Additionally, in the soleus muscle, FCX supplementation significantly elevated genes that regulate mitochondrial biogenesis and fatty acid β-oxidation, concomitantly increasing mitochondrial DNA copy number, compared with HFC. In summary, FCX supplementation had minor effects on hepatic and white adipose inflammation and fibrosis in two different DIO mouse models.
format Online
Article
Text
id pubmed-9183127
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91831272022-06-10 Consumption of Low Dose Fucoxanthin Does Not Prevent Hepatic and Adipose Inflammation and Fibrosis in Mouse Models of Diet-Induced Obesity Kim, Mi-Bo Bae, Minkyung Lee, Yoojin Kang, Hyunju Hu, Siqi Pham, Tho X. Park, Young-Ki Lee, Ji-Young Nutrients Article Fucoxanthin (FCX) is a xanthophyll carotenoid present in brown seaweed. The goal of this study was to examine whether FCX supplementation could attenuate obesity-associated metabolic abnormalities, fibrosis, and inflammation in two diet-induced obesity (DIO) mouse models. C57BL/6J mice were fed either a high-fat/high-sucrose/high-cholesterol (HFC) diet or a high-fat/high-sucrose (HFS) diet. The former induces more severe liver injury than the latter model. In the first study, male C57BL/6J mice were fed an HFC diet, or an HFC diet containing 0.015% or 0.03% (w/w) FCX powder for 12 weeks to develop obesity-induced nonalcoholic steatohepatitis (NASH). In the second study, mice were fed an HFS diet or an HFS diet containing 0.01% FCX powder for 8 weeks. FCX did not change body weight gain and serum lipid profiles compared to the HFC or HFS controls. No significant differences were present in liver triglyceride and total cholesterol, hepatic fat accumulation, and serum alanine aminotransferase levels between control and FCX-fed mice regardless of whether they were on an HFC or HFS diet. FCX did not mitigate mRNA abundance of genes involved in lipid synthesis, cholesterol metabolism, inflammation, and fibrosis in the liver and white adipose tissue, while hepatic fatty acid β-oxidation genes were significantly elevated by FCX in both HFC and HFS feeding studies. Additionally, in the soleus muscle, FCX supplementation significantly elevated genes that regulate mitochondrial biogenesis and fatty acid β-oxidation, concomitantly increasing mitochondrial DNA copy number, compared with HFC. In summary, FCX supplementation had minor effects on hepatic and white adipose inflammation and fibrosis in two different DIO mouse models. MDPI 2022-05-29 /pmc/articles/PMC9183127/ /pubmed/35684079 http://dx.doi.org/10.3390/nu14112280 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kim, Mi-Bo
Bae, Minkyung
Lee, Yoojin
Kang, Hyunju
Hu, Siqi
Pham, Tho X.
Park, Young-Ki
Lee, Ji-Young
Consumption of Low Dose Fucoxanthin Does Not Prevent Hepatic and Adipose Inflammation and Fibrosis in Mouse Models of Diet-Induced Obesity
title Consumption of Low Dose Fucoxanthin Does Not Prevent Hepatic and Adipose Inflammation and Fibrosis in Mouse Models of Diet-Induced Obesity
title_full Consumption of Low Dose Fucoxanthin Does Not Prevent Hepatic and Adipose Inflammation and Fibrosis in Mouse Models of Diet-Induced Obesity
title_fullStr Consumption of Low Dose Fucoxanthin Does Not Prevent Hepatic and Adipose Inflammation and Fibrosis in Mouse Models of Diet-Induced Obesity
title_full_unstemmed Consumption of Low Dose Fucoxanthin Does Not Prevent Hepatic and Adipose Inflammation and Fibrosis in Mouse Models of Diet-Induced Obesity
title_short Consumption of Low Dose Fucoxanthin Does Not Prevent Hepatic and Adipose Inflammation and Fibrosis in Mouse Models of Diet-Induced Obesity
title_sort consumption of low dose fucoxanthin does not prevent hepatic and adipose inflammation and fibrosis in mouse models of diet-induced obesity
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9183127/
https://www.ncbi.nlm.nih.gov/pubmed/35684079
http://dx.doi.org/10.3390/nu14112280
work_keys_str_mv AT kimmibo consumptionoflowdosefucoxanthindoesnotpreventhepaticandadiposeinflammationandfibrosisinmousemodelsofdietinducedobesity
AT baeminkyung consumptionoflowdosefucoxanthindoesnotpreventhepaticandadiposeinflammationandfibrosisinmousemodelsofdietinducedobesity
AT leeyoojin consumptionoflowdosefucoxanthindoesnotpreventhepaticandadiposeinflammationandfibrosisinmousemodelsofdietinducedobesity
AT kanghyunju consumptionoflowdosefucoxanthindoesnotpreventhepaticandadiposeinflammationandfibrosisinmousemodelsofdietinducedobesity
AT husiqi consumptionoflowdosefucoxanthindoesnotpreventhepaticandadiposeinflammationandfibrosisinmousemodelsofdietinducedobesity
AT phamthox consumptionoflowdosefucoxanthindoesnotpreventhepaticandadiposeinflammationandfibrosisinmousemodelsofdietinducedobesity
AT parkyoungki consumptionoflowdosefucoxanthindoesnotpreventhepaticandadiposeinflammationandfibrosisinmousemodelsofdietinducedobesity
AT leejiyoung consumptionoflowdosefucoxanthindoesnotpreventhepaticandadiposeinflammationandfibrosisinmousemodelsofdietinducedobesity